Abstract
Introduction
MicroRNAs are a recently discovered class of naturally occurring short non-coding RNA molecules that regulate eukaryotic gene expression through binding to complementary sequences in the 3ЈUTR of target mRNA. There are currently over 600 annotated human microRNAs in the miRBase database (http: //microrna. sanger.ac.uk/sequences/) although the true total number of microRNAs is predicted to be closer to 1000 [1, 2] . It is currently believed that between 10-30% of all human genes are a target for microRNA regulation [3] . MicroRNAs play key regulatory roles in a diverse range of pathways including control of haematopoiesis, developmental timing, cell differentiation, apoptosis, cell proliferation and organ development [4] . The [5] , and there is rapidly accumulating evidence to signify that dysfunctional expression of microRNAs is a common feature of malignancy [6, 7] . MicroRNAs have been demonstrated to have diagnostic and prognostic potential in cancer [8] [9] [10] [11] and it has been suggested that microRNA expression profiling can distinguish cancers according to both the cellular nature and the developmental stage of the tumour with a greater degree of accuracy than traditional gene expression analysis [12] . Diffuse large B-cell lymphoma (DLBCL) is the most common form of adult lymphoma accounting for nearly 40% of all lymphoid tumours [13] . Despite improvements in treatment regimes, the majority of patients succumb to this aggressive disease. [14, 15] . Using a prototypic cell line model, we previously identified microRNAs associated with these two DLBCL subtypes [10] . However 
DLBCL is characterized by marked clinical and pathological heterogeneity that is reflected at the molecular level. Gene expression and immunohistochemical studies have revealed the presence of at least two distinct molecular subtypes of DLBCL: those that are germinal centre B-cell-like (GCB) and those that are non-germinal centre-like (NGC)

Materials and methods
Patient samples
Details of the haematological cell lines (n ϭ 40) and lymphocyte subsets (n ϭ 12) used in unsupervised cluster analysis have been previously described [16] [15] .
RNA purification and microarray analysis
Total RNA was purified from 4 ϫ 20 m FFPE sections using the Recoverall kit from Ambion (Huntington, UK) in accordance with the manufacturers' instructions. RNA (3 g ) were labelled and hybridized to RNA microarrays as previously described [16] with normal samples. (Fig. 1B) [18] ) and 92/97 (95%) of cases in the extended cohort. Again, the two sets of samples were found to cluster distinctly using the 26-microRNA signature (Fig. 2B ). [15] , other studies did not reach the same conclusion [19, 20] . We did not find an association between immunophenotype and outcome in our cohort (P ϭ 0.265; Fig. S2 (Fig. 4) . Additionally miR-142, (Fig. S5) .
MicroRNA expression varies between GC and NGC immunophenotypes of DLBCL
MicroRNA expression is associated with clinical outcome in de novo DLBCL
While some studies have found that GC-and NGC-immunophenotypes have a prognostic significance in DLBCL
High-grade transformation of FCL to DLBCL is associated with changes in microRNA expression
To investigate whether changes in microRNA expression were associated with transformation we first looked at differences between de novo (DLBCL de novo [n ϭ 64]) and transformed (DLBCL-t [n ϭ 16]) cases of DLBCL. Fourteen microRNAs (Table 6) were found to be differentially expressed (P Ͻ 0.05). These microRNAs correctly predicted transformation status in 73/80 (91%) of samples. Next we compared FCL cases that subsequently underwent highgrade transformation (FCL-t [n ϭ 7]) with cases that did not (FCL-nt [n ϭ 11]). Six microRNAs were differentially expressed (P Ͻ 0.05) between these two groups (Table S3), whose expression levels correctly predicted 16/18 (89%) of cases. All of these microRNAs had significantly (P Ͻ 0.05) different expression levels between FCL-t and FCL-nt cases as measured by independent t-test
Discussion
Aberrant expression of microRNAs is now well established in many cancer types [22] . Despite this, the role and identity of lymphoma-associated microRNAs is only poorly understood [23] . Therefore, we undertook a comprehensive investigation of microRNA expression in two of the most frequently occurring lymphomas, DLBCL and FCL, using a microRNA microarray platform containing 464 human probes (miRBase v.9.0) [16] .
Although we had already made some progress in identifying lymphoma-associated microRNAs by profiling a large number of lymphoma cell lines [16] , unsupervised cluster analysis showed that clinical samples had a discrete microRNA pattern from the cell lines (Fig. 1A) [24] and miR-21 is up-regulated in many cancer types including lymphoma [10, 25] . Interestingly miR-9 has been shown to target PRDM1/Blimp-1 in lymphomas [26] which is consistent with the down-regulation of PRDM1/Blimp-1 expression in DLBCL [27] . Although down-regulated in colorectal carcinoma [28] and some lymphomas [29] we found that miR-143 and miR-145 were up-regulated in DLBCL and FCL. has been demonstrated to be a key regulator of B-cell development [31, 32] , and its down-regulation has previously been noted in DLBCL and FCL [10, 16] . Down-regulation of miR-223 has also been shown in hepatocellular carcinomas [33] . A recent study examined expression of 157 microRNAs in 58 DLBCL, and 46 FCL cases as well as 7 reactive lymph nodes [18] .
This identified 12 microRNAs differentially expressed between lymphoma and reactive lymph node samples. Three of these microRNAs were included in our list of 20 most discriminatory microRNAs (miR-155, miR-150 and miR-145), and a further two
Fig. 3 Kaplan-Meier survival curves of EFS in DLBCL patients based on high or low (median) expression levels of microRNAs (P Ͻ 0.05). Curves were compared by univariate (log-rank) analysis. (A) miR-637, (B) miR-608, (C) miR-302, (D) miR-330, (E) miR-30e-3p, (F) miR-425, (G) miR-27a, (H) miR-24, (I) miR-23a, (J) miR-199b, (K) miR-199a* and (L) miR-100.
(miR-99a and miR-10a) had a P-value of Ͻ 0.05. The 12-microRNAs identified by Roehle et [34] . The other four microRNAs encoded [34] . Moreover, direct binding of the c-myc protein up-regulates miR-17-92 expression [35] and over-expression of c-myc has been demonstrated in the majority (66.6%) of DLBCL cases [36] , which has also been associated with poorer outcome [37] . An increased level of this cluster in DLBCL compared to FCL is consistent with a more aggressive clinical phenotype of DLBCL. [15] . With the exception of miR-181a and miR-324, which are probably cell line specific, all of the microRNAs differentially expressed in the cell line model of GC-and NGC-type DLBCL [10, 16] were also differentially expressed in clinical cases. miR-155 expression has also been shown by other groups to be more highly expressed in DLBCL with a NGC-immunophenotype [38, 39] . Interestingly miR-221 and miR-222 have been found to target p27(Kip1) [40] . As p27 protein levels are higher in GC-than NGC-type DLBCL [41] , these results are consistent with differential expression between the two immunophenotypes.
Fig. 4 Kaplan-Meier survival curves of EFS in DLBCL patients treated with R-CHOP based on high or low (median) expression levels of microRNAs (P Ͻ 0.1). Curves were compared by univariate (log-rank) analysis. (A) miR302b, (B) miR-330, (C) miR-425, (D) miR-27a, (E) miR-199b, (F) miR-142, (G) miR-519d and (H) miR
As we had previously identified microRNAs associated with the two subtypes of DLBCL (GC-and NGC-type) in a cell line model, we sought to extend this work by looking for differences between clinical cases of DLBCL de novo that had been immunoclassified as GC-or NGC-type according to the Hans algorithm
Roehle et al. reported that they could not readily discriminate between immunophenotype on the basis of their results although they did identify nine differentially expressed microRNAs, using a false discovery rate cutoff of 20% [18] . Four of these (miR-155, miR-199b, miR- 
Expression levels of microRNAs are associated with survival in DLBCL patients
Despite the use of rituximab-based chemotherapy regimens that allow 60-80% of DLBCL patients to reach a complete remission, the response to treatment remains variable, and a substantial proportion of DLBCL patients will still succumb to this disease [13] . We therefore sought to identify microRNAs that were associated with outcome. As the gold-standard for prognostication of DLBCL remains the IPI, we firstly examined microRNAs associated with IPI status. Splitting the DLBCL de novo cases for which we had clinical data (n ϭ 61) into low (0, 1, 2) and high (3, 4, 5) IPI class, we identified thirteen microRNAs that correctly predicted 85% of cases.
In order to see whether microRNA expression could predict outcome we analysed EFS in the DLBCL de novo patients and identified 21 differentially expressed microRNAs. 82% of cases had outcome predicted using these microRNAs. Seven of these (miR-23a, miR-27a, miR-19a, miR-21, miR-92, miR-222 and miR-142) were also found to be associated with survival by Roehle et al. [18] . We carried out univariate analysis on the expression levels of these microRNAs individually and found that 12 were significantly associated with EFS (Fig. 3) . As not all of the patients in our cohort were treated with a rituximab containing regimen we re-applied univariate analysis for the 21 microRNAs to patients who were uniformly treated with R-CHOP (n ϭ 38). Although the number of patients was small, eight of these microRNAs were still associated with EFS (Fig. 4) . High expression of miR-142, miR-302b, and miR-519d and low expression of miR-330, miR-425, miR-27a, miR-199b and miR-222 were associated with poor outcome in these patients. Despite reportedly being oncogenic in breast cancer cell lines [42] , our study and that of Roehle et al. [18] found that decreased expression of miR-27a was associated with poor prognosis. Recently miR-302b has been found to be expressed abundantly in embryonic stem cells and is capable of re-programming cancer cells into a pluripotent state [43] . Down-regulation of miR-199b was most significantly associated with poor outcome, whether patients received a rituximab-containing regimen or not (P Ͻ 0.0001 and 0.01, respectively). Interestingly, expression of miR-199b was also found to be associated with the GCimmunophenotype (Table 3) , which in some studies is linked to a better outcome [15] . Consistent with these data, down-regulation of miR-199 has been associated with tumour progression through targeting of IKK-␤ [44] , an enhancer of NF-␤ activity and constitutive NF-␤ activation is a hallmark of DLBCL with a poorer response to treatment [45] . (Fig. S5) . Members of the let-7 family have been shown to target c-myc expression in Burkitt lymphoma [48] and decreased c-myc expression has been associated with high-grade transformation of FCL to DLBCL [47] . Although 
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